Scilex Holding (SCLXW) Other financing activities (2020 - 2024)
Scilex Holding (SCLXW) recorded quarterly Other financing activities of $200000.0 in Q4 2024, up 107.06% quarter-over-quarter from -$2.8 million in Q3 2024, and down 47.37% on a YoY basis from $380000.0 in Q1 2024.
Scilex Holding (SCLXW) Other financing activities (2020 - 2024) Analysis & Trends
Scilex Holding's Other financing activities history runs 4 years deep, the most recent figure standing at $200000.0 for Q4 2024.
- In Q4 2024, Other financing activities fell 47.37% year-over-year to $200000.0; the TTM figure through Sep 2025 stood at $200000.0 (down 47.37% YoY), while the FY2024 annual figure was $200000.0, down 47.37% from the prior year.
- Other financing activities was $200000.0 for Q4 2024 at Scilex Holding, up from -$2.8 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $1.6 million in Q2 2024 to a low of -$2.8 million in Q3 2024.
- Historically, Other financing activities has averaged $59114.8 across 4 years, with a median of $200000.0 in 2024.
- The sharpest annual moves came in 2021 and 2024: Other financing activities slumped 692.3% in 2021, then jumped 309.74% in 2024.
- A 4-year view of Other financing activities shows it stood at $118213.0 in 2020, then sank by 452.13% to -$416260.0 in 2021, then surged by 191.29% to $380000.0 in 2023, then tumbled by 47.37% to $200000.0 in 2024.
- The last three Other financing activities figures came in at $200000.0 (Q4 2024), -$2.8 million (Q3 2024), and $1.6 million (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 200,000.00 |
| Dec 31, 2024 | 200,000.00 |
| Sep 30, 2024 | -2.83 Mn |
| Sep 30, 2024 | -2.83 Mn |
| Jun 30, 2024 | 1.56 Mn |
| Jun 30, 2024 | 1.56 Mn |
| Mar 31, 2024 | 1.28 Mn |
| Mar 31, 2024 | 1.28 Mn |
| Dec 31, 2023 | 380,000.00 |
| Dec 31, 2023 | 380,000.00 |
| Sep 30, 2023 | -380,000.00 |
| Sep 30, 2023 | -380,000.00 |
| Jun 30, 2023 | 380,000.00 |
| Jun 30, 2023 | 380,000.00 |
| Dec 31, 2021 | -416,260.00 |
| Dec 31, 2021 | -416,260.00 |
| Sep 30, 2021 | -416,260.00 |
| Sep 30, 2021 | -416,260.00 |
| Jun 30, 2021 | 416,260.00 |
| Jun 30, 2021 | 416,260.00 |